文献速递心力衰竭与心肌病

克隆性造血与心力衰竭发病风险的关联研究

Supplemental Association of Clonal Hematopoiesis With Incident Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

该研究基于5个队列56,597名无心力衰竭或血液系统恶性肿瘤的参与者,通过全外显子或全基因组测序检测CHIP状态,中位随访长达20年。结果显示CHIP与心力衰竭发病风险增加25%相关(HR 1.25,95%CI 1.13-1.38),其中ASXL1、TET2和JAK2变异与风险增加相关,而DNMT3A变异无显著关联。

要点

  • CHIP是无症状个体中克隆扩增的致白血病序列变异,与心力衰竭发病风险独立相关。
  • ASXL1、TET2和JAK2变异与心衰风险增加相关,DNMT3A变异则无显著关联。
  • 大克隆CHIP(VAF>10%)与心衰风险增加关联更强(HR 1.29,95%CI 1.15-1.44)。

核心结论

  • CHIP,尤其是ASXL1、TET2和JAK2序列变异,是心力衰竭的新危险因素。

研究设计与样本

  • 研究纳入5个队列中无心力衰竭或血液系统恶性肿瘤的参与者,通过全外显子或全基因组测序检测血液DNA的CHIP状态。
  • 共纳入56,597名个体(59%女性,基线平均年龄58岁),其中3,406名(6%)存在CHIP,随访长达20年。
  • 采用Cox比例风险模型在各队列内校正人口学和临床危险因素,并进行固定效应荟萃分析。

主要发现

  • 在荟萃分析中,CHIP与心力衰竭发病风险增加25%相关(HR 1.25;95%CI 1.13-1.38),各队列间关联一致。
  • ASXL1、TET2和JAK2序列变异分别与心力衰竭风险增加相关,而DNMT3A序列变异与心力衰竭无显著关联。
  • 次要分析提示大克隆CHIP(定义为变异等位基因频率>10%)与更高的心力衰竭风险相关(HR 1.29;95%CI 1.15-1.44)。
  • CHIP与伴有或不伴有基线冠心病的心力衰竭关联具有同质性。
  • ASXL1序列变异与左心室射血分数降低相关。

临床怎么用

  • 对于携带CHIP(尤其是ASXL1、TET2、JAK2变异)的无症状个体,应关注心力衰竭风险,考虑纳入心血管风险评估。
  • 大克隆CHIP(VAF>10%)可能提示更高的心衰风险,需加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Age-related clonal hematopoiesis of indeterminate potential (CHIP), defined as clonally expanded leukemogenic sequence variations (particularly in DNMT3A, TET2, ASXL1, and JAK2) in asymptomatic individuals, is associated with cardiovascular events, including recurrent heart failure (HF). OBJECTIVES: This study sought to evaluate whether CHIP is associated with incident HF. METHODS: CHIP status was obtained from whole exome or genome sequencing of blood DNA in participants without prevalent HF or hematological malignancy from 5 cohorts. Cox proportional hazards models were performed within each cohort, adjusting for demographic and clinical risk factors, followed by fixed-effect meta-analyses. Large CHIP clones (defined as variant allele frequency >10%), HF with or without baseline coronary heart disease, and left ventricular ejection fraction were evaluated in secondary analyses. RESULTS: Of 56,597 individuals (59% women, mean age 58 years at baseline), 3,406 (6%) had CHIP, and 4,694 developed HF (8.3%) over up to 20 years of follow-up. CHIP was prospectively associated with a 25% increased risk of HF in meta-analysis (hazard ratio: 1.25; 95% confidence interval: 1.13-1.38) with consistent associations across cohorts. ASXL1, TET2, and JAK2 sequence variations were each associated with an increased risk of HF, whereas DNMT3A sequence variations were not associated with HF. Secondary analyses suggested large CHIP was associated with a greater risk of HF (hazard ratio: 1.29; 95% confidence interval: 1.15-1.44), and the associations for CHIP on HF with and without prior coronary heart disease were homogenous. ASXL1 sequence variations were associated with reduced left ventricular ejection fraction. CONCLUSIONS: CHIP, particularly sequence variations in ASXL1, TET2, and JAK2, represents a new risk factor for HF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Yu B, Roberts MB, Raffield LM, et al. Supplemental Association of Clonal Hematopoiesis With Incident Heart Failure. J Am Coll Cardiol. 2021. PMID: 34210413. doi:10.1016/j.jacc.2021.04.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。